Match!
Ioanna Xanthopoulou
University of Patras
155Publications
20H-index
1,852Citations
Publications 158
Newest
Background The risk of recurrent ischemia and bleeding after percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS) may vary during the first year of follow-up according to clinical presentation, and medical and interventional strategies. Methods BleeMACS and RENAMI are 2 multicenter registries enrolling patients with ACS treated with PCI and clopidogrel, prasugrel, or ticagrelor. The average daily ischemic and bleeding risks (ADIR and ADBR) in the first year after PCI were t...
Source
The association between prior stroke/transient ischemic attack (TIA) and clinical outcomes in patients with acute coronary syndrome (ACS) has not been well explored. We evaluated the impact of prio...
Source
Abstract Background The PRECISE-DAPT and PARIS risk scores (RSs) were recently developed to help clinicians at individualizing the optimal dual antiplatelet therapy duration (DAPT) after percutaneous coronary intervention (PCI). Nevertheless, external validation of these RSs it has not yet been performed in ACS (acute coronary syndrome) patients treated with prasugrel or ticagrelor in a real- world scenario. Methods 4424 ACS patients who underwent PCI and survived to hospital discharge, from Jan...
Source
#1Mattia Peyracchia (UNITO: University of Turin)H-Index: 1
#2Andrea Saglietto (UNITO: University of Turin)H-Index: 5
Last.Fabrizio D´Ascenzo (UNITO: University of Turin)H-Index: 36
view all 50 authors...
Introduction Real-life data comparing clopidogrel, prasugrel, and ticagrelor for unselected patients undergoing percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS) are lacking, as are data for the temporal distribution of ischemic and bleeding risks.
Source
Source
#1Ovidio De Filippo (UNITO: University of Turin)H-Index: 3
#2Fabrizio D´Ascenzo (UNITO: University of Turin)H-Index: 36
Last.Gaetano Maria De Ferrari (UNITO: University of Turin)H-Index: 1
view all 55 authors...
Source
#1Federico Conrotto (UNITO: University of Turin)H-Index: 13
#2Maurizio Bertaina (UNITO: University of Turin)H-Index: 6
Last.Fabrizio D´Ascenzo (UNITO: University of Turin)H-Index: 36
view all 38 authors...
Introduction:The safety and efficacy of prasugrel and ticagrelor in patients with diabetes mellitus presenting with acute coronary syndrome and treated with percutaneous coronary intervention remai...
3 CitationsSource
Resumen Introduccion y objetivos No esta clara la asociacion entre los inhibidores de la enzima de conversion de la angiotensina (IECA) o los antagonistas del receptor de la angiotensina II (ARA-II) y la mortalidad de los pacientes con sindrome coronario agudo (SCA) sometidos a intervencion coronaria percutanea (ICP) con fraccion de eyeccion del ventriculo izquierdo (FEVI) conservada. Nuestro objetivo es determinar dicha asociacion en pacientes con FEVI conservada o reducida. Metodos Se analizar...
Source
#1Ovidio De Fillippo (UNITO: University of Turin)H-Index: 1
#2Martina Cortese (UNITO: University of Turin)H-Index: 1
Last.Mauro Rinaldi (UNITO: University of Turin)H-Index: 31
view all 38 authors...
1 CitationsSource
#1Ovidio De Filippo (UNITO: University of Turin)H-Index: 3
#2Martina Cortese (UNITO: University of Turin)H-Index: 1
Last.Mauro Rinaldi (UNITO: University of Turin)H-Index: 31
view all 38 authors...
Background Limited data are available concerning differences in clinical outcomes for real-life patients treated with ticagrelor versus prasugrel after percutaneous coronary intervention (PCI).
2 CitationsSource
12345678910